Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 6, 2017, Pages 431-437

  Zoungas, Sophia ^a,b   Arima, Hisatomi ^a,c   Gerstein, Hertzel C ^d   Holman, Rury R ^e   Woodward, Mark ^a,f,g   Reaven, Peter ^h   Hayward, Rodney A ⁱ   Craven, Timothy ^j   Coleman, Ruth L ^e   Chalmers, John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c FUKUOKA UNIVERSITY   (Japan)

^d HAMILTON HEALTH SCIENCES   (Canada)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h CARL T HAYDEN VA MEDICAL CENTER   (United States)

ⁱ VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^j WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLUCOSE; HEMOGLOBIN A1C; ANTIDIABETIC AGENT;

ARTICLE; BLOOD GLUCOSE MONITORING; CATARACT EXTRACTION; CLINICAL OUTCOME; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; LASER COAGULATION; MACROALBUMINURIA; MACULAR EDEMA; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFLEX DISORDER; RISK REDUCTION; SENSORY DYSFUNCTION; VISUAL IMPAIRMENT; VITRECTOMY; COMPLICATION; DIABETIC COMPLICATION; DRUG EFFECTS; EYE DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; MALE; META ANALYSIS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; THEORETICAL MODEL;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EYE DISEASES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MODELS, THEORETICAL; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 85016474227     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30104-3     Document Type: Article

References (18)

1. International Diabetes Federation. IDF diabetes atlas, 7th edn., 2015, International Diabetes Federation, Brussels.
2. Gregg, EW, Li, Y, Wang, J, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 370 (2014), 1514–1523.
3. Rossing, P, de Zeeuw, D, Need for better diabetes treatment for improved renal outcome. Kidney Int 79 (2011), S28–S32.
4. Boussageon, R, Bejan-Angoulvant, T, Saadatian-Elahi, M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ, 343, 2011, d4169.
5. Hemmingsen, B, Lund, SS, Gluud, C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ, 343, 2011, d6898.
6. Coca, SG, Ismail-Beigi, F, Haq, N, Krumholz, HM, Parikh, CR, Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 172 (2012), 761–769.
7. Hemmingsen, B, Lund, SS, Gluud, C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev, 11, 2013 CD008143.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
9. Gerstein, HC, Miller, ME, Byington, RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
10. Patel, A, MacMahon, S, Chalmers, J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
11. Duckworth, W, Abraira, C, Moritz, T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
12. Turnbull, FM, Abraira, C, Anderson, RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52 (2009), 2288–2298.
13. Levey, AS, Eckardt, KU, Tsukamoto, Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int, 67, 2005, 2089.
14. Saran, R, Li, Y, Robinson, B, et al. US Renal Data System 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 67:suppl 1 (2016), S1–434.
15. Ismail-Beigi, F, Craven, T, Banerji, MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376 (2010), 419–430.
16. Stratton, IM, Adler, AI, Neil, HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000), 405–412.
17. 1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 55 (2012), 636–643.
18. Inzucchi, SE, Bergenstal, RM, Buse, JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55 (2012), 1577–1596.